<DOC>
	<DOCNO>NCT02423837</DOCNO>
	<brief_summary>- To evaluate efficacy bendamustine combination rituximab first line patient follicular lymphoma , 1-3A cytological type . - To evaluate safety , tolerability feasibility bendamustine combination rituximab 1st line patient follicular lymphoma , 1-3A cytological type . - To evaluate impact regimen modification ( bendamustine dose modification and/or extension inter-cycle interval ) duration complete partial response . - To evaluate estimate treatment duration , reason treatment withdrawal . - To evaluate possibility unification standardization therapy protocol BR ( rituximab 375 mg/m2 day 1 bendamustine 90 mg/m2 day 1-2 ) . - To evaluate factor affect overall progression-free survival .</brief_summary>
	<brief_title>Bendamustine Combination With Rituximab First-line Therapy Followed Maintenance Therapy With Rituximab Patients With Follicular Lymphoma</brief_title>
	<detailed_description>Protocol involve 6 course rituximab bendamustine 26 day interval course ( one cycle continue 28 day ) . Control examination perform every two course ( 28 , 56 , 84 day treatment ) include ( physical examination , monitor clinical blood test , biochemical blood test , compute tomography , ultrasonography , patient gastrointestinal tract involvement - fibrogastroduodenoscopy colonoscopy ) . Efficacy therapeutic impact estimate rate complete remission , partial remission , stable disease progression base tumor size reduction compare pretreatment data evaluate use compute tomography express percentage . Patients partial complete remission stable disease 2 course continue treatment . Patients tumor progression exclude issue . Patients achieve complete remission 2 course may end treatment 4 course . Safety , tolerability feasibility imply hematologic non-hematologic toxicity estimate use data physical examination , monitor clinical blood test , biochemical blood test bone marrow analysis ( cytological , morphological genetic test ) .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Patients diagnosis follicular lymphoma confirm immunohistochemistry ( IHC ) analysis reference laboratory Written inform consent use personal data approve Independent Ethic Committee Men woman patient , 1875 year old ECOG performance status â‰¤ 3 No previous treatment chemotherapy and/or radiation therapy follicular lymphoma The patient participate clinical trial and/or receive experimental treatment . Transformation follicular lymphoma large cell lymphoma ( example , follicular lymphoma IIIB graduation , diffuse large Bcell lymphoma ) . Central nervous system involvement . The presence second malignancy within last 5 year prior inclusion study except adequately treat basal cell squamous cell skin cancer , situ cervical cancer prostate cancer . Clinically significant cardiovascular cerebrovascular disease past 6 month , acute myocardial infarction , unstable angina , significant ventricular arrhythmia , severe heart failure ( NYNA class IV ) , stroke , uncontrolled hypertension . Renal impairment ( serum creatinine &gt; 150 umol/L ) , except lymphoid infiltration kidney tumor lysis syndrome . Liver failure ( except leukemic/lymphoid organ infiltration ) , acute hepatitis ( serum bilirubin &gt; 2 x ULN , activity ALT AST &gt; 4 x ULN , prothrombin index &lt; 50 % ) . Uncontrolled diabetes mellitus ( serum glucose &gt; 15 mmol/L ) Sepsis ( septicopyemic focus , hemodynamic instability , inefficiency antibacterial therapy ) acute infectious disease . HIV , hepatitis B C ( include absence Hbc Hbs antibody ) . Lifethreatening bleeding , except bleed gastrointestinal tract cause neoplastic process . Severe mental disorder ( schizophrenia , major depressive syndrome productive symptom ) . Physical failure require constant care , cachexia ( total protein &lt; 35 g/L ) . Known hypersensitivity rituximab component . Known hypersensitivity bendamustine component . Pregnant currently breastfeed woman Neutrophils count &lt; 1500/mm3 and/or platelet count &lt; 75000/mm3 . Surgery prior 15 day therapy initiation . In case serious infectious complication relief , uncontrolled diabetes , hemorrhagic syndrome , hypertension patient may include study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>follicular lymphoma</keyword>
	<keyword>bendamustine</keyword>
	<keyword>rituximab</keyword>
</DOC>